Your browser doesn't support javascript.
loading
Continued mitigation needed to minimise the high health burden from COVID-19 in Aotearoa New Zealand.
Baker, Michael G; Kvalsvig, Amanda; Plank, Michael J; Geoghegan, Jemma L; Wall, Teresa; Tukuitonga, Collin; Summers, Jennifer; Bennett, Julie; Kerr, John; Turner, Nikki; Roberts, Sally; Ward, Kelvin; Betty, Bryan; Huang, Q Sue; French, Nigel; Wilson, Nick.
Afiliación
  • Baker MG; Epidemiologist and Public Health Physician, University of Otago Wellington.
  • Kvalsvig A; Epidemiologist, University of Otago Wellington.
  • Plank MJ; Mathematical Modeler, School of Mathematics and Statistics, University of Canterbury, Co-lead Covid-19 Modelling Aotearoa.
  • Geoghegan JL; Molecular biologist, Department of Microbiology and Immunology, University of Otago Dunedin.
  • Wall T; Consultant on strengthening Maori health and equity, Wellington.
  • Tukuitonga C; Public Health Physician, Pacific Health Researcher, The University of Auckland.
  • Summers J; Epidemiologist, University of Otago Wellington.
  • Bennett J; Epidemiologist, University of Otago Wellington.
  • Kerr J; Senior Research Fellow, University of Otago Wellington.
  • Turner N; General Practitioner and Medical Director of the Immunisation Advisory Centre, The University of Auckland.
  • Roberts S; Clinical Microbiologist, Clinical Head of Microbiology and Infection Prevention and Control, Auckland Hospital, Te Whatu Ora - Health New Zealand, Te Toka Tumai Auckland.
  • Ward K; Urgent Care Physician, Wellington.
  • Betty B; General Practitioner and Chair, General Practice New Zealand, Wellington.
  • Huang QS; Virologist, Director of WHO National Influenza Centre, Institute of Environmental Science and Research, Wellington.
  • French N; Epidemiologist, Massey University of New Zealand, Palmerston North.
  • Wilson N; Epidemiologist and Public Health Physician, University of Otago Wellington.
N Z Med J ; 136(1583): 67-91, 2023 Oct 06.
Article en En | MEDLINE | ID: mdl-37797257
ABSTRACT
In this article we review the COVID-19 pandemic experience in Aotearoa New Zealand and consider the optimal ongoing response strategy. We note that this pandemic virus looks likely to result in future waves of infection that diminish in size over time, depending on such factors as viral evolution and population immunity. However, the burden of disease remains high with thousands of infections, hundreds of hospitalisations and tens of deaths each week, and an unknown burden of long-term illness (long COVID). Alongside this there is a considerable burden from other important respiratory illnesses, including influenza and RSV, that needs more attention. Given this impact and the associated health inequities, particularly for Maori and Pacific Peoples, we consider that an ongoing respiratory disease mitigation strategy is appropriate for New Zealand. As such, the previously described "vaccines plus" approach (involving vaccination and public health and social measures), should now be integrated with the surveillance and control of other important respiratory infections. Now is also a time for New Zealand to build on the lessons from the COVID-19 pandemic to enhance preparedness nationally and internationally. New Zealand's experience suggests elimination (or ideally exclusion) should be the default first choice for future pandemics of sufficient severity.
Asunto(s)
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: N Z Med J Año: 2023 Tipo del documento: Article
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans País/Región como asunto: Oceania Idioma: En Revista: N Z Med J Año: 2023 Tipo del documento: Article